"Glycosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed)
| Descriptor ID |
D006027
|
| MeSH Number(s) |
D09.408
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycosides".
Below are MeSH descriptors whose meaning is more specific than "Glycosides".
This graph shows the total number of publications written about "Glycosides" by people in this website by year, and whether "Glycosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycosides" by people in Profiles.
-
Prospective insight into the role of benzyl propylene glycoside as a modulator of the cGAS-STING signaling pathway in the management of nonalcoholic fatty pancreas animal model. Biol Res. 2023 Mar 13; 56(1):11.
-
Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12?weeks: The inTandem4 trial. Diabetes Obes Metab. 2019 11; 21(11):2440-2449.
-
Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-?B and MAPK pathways. J Cell Physiol. 2019 08; 234(10):17600-17611.
-
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 05; 42(5):919-930.
-
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 Sep; 41(9):1970-1980.
-
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. Diabetes Care. 2018 Sep; 41(9):1981-1990.
-
Two new thiophene polyacetylene glycosides from Atractylodes lancea. J Asian Nat Prod Res. 2018 Jun; 20(6):531-537.
-
Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. J Antimicrob Chemother. 2018 02 01; 73(2):448-451.
-
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348.
-
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul; 38(7):1181-8.